secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-04-07T23:59:59+00:00
Accession:  0001193125-22-098229
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics raises ~$55M in private placement; amends SVB loan facility
------------------------------------------------------------------------------

- Gross proceeds ~$55M from sale of 4.58M shares at $1.90/share and pre-funded warrants for 24.38M shares at $1.899.
- Co-lead investors: Frazier Life Sciences and Venrock; also Fairmount and New Enterprise Associates participating.
- Proceeds to fund clinical development of Haduvio for chronic cough in IPF patients and for working capital.
- Loan amendment with SVB: upon raising $45M net equity, milestones terminate; interest rate becomes prime+3% (floor 6.25%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312522098229/0001193125-22-098229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312522098229/d324144d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-098229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer